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Abstract
Background: Heart failure has become one of the major causes of hospitalization worldwide. Hypertension,
diabetes mellitus and hyperlipidemia are the major causes of heart failure. In order to effectively prevent heart
failure, blood pressure, blood glucose and cholesterol levels shall be closely monitored and controlled as well as
medication adherence. This study aimed to investigate the role of pharmacist intervention in prevention of heart
failure in high risk elderly patients in the community of Hong Kong.
Aim: This study aimed to investigate the role of pharmacist intervention in prevention of heart failure in highrisk
elderly patients in the community of Hong Kong.
Methods: This prospective uncontrolled study was conducted between July 2012 and April 2013 with two revisits
every 3 to 4 months to review elderly patients’ medication profiles as well as assess their blood pressure (BP),
random capillary blood glucose (RCBG) level, cholesterol levels, signs and symptoms of heart failure and the
compliance level. The results collected at the baseline data were analyzed and compared with those collected at
the last follow-up visit.
Result: A significant increase in number of subjects free of symptoms of heart failure (31.88%, p < 0.001) was found.
For chronic disease management, significant reduction in LDL-cholesterol level (-0.86 ± 0.56mmol/L, p = 0.038) and
triglyceride level (-1.15 ± 1.09mmol/L, p < 0.001) was observed in overall participants. Yet, no significant reduction in
BP level or RCBG level was observed in overall subjects. Significant reduction in mean Morisky Medication
Adherence Score (-0.54 ± 1.50, p = 0.005) indicated improvement in medication compliance in participants.
Conclusion: The Pharmacy Outreach service has a significant role in prevention of heart failure, by means of minimizing
heart failure symptoms, improving medication compliance and enhancing chronic disease management, particularly
cholesterol management in community elderly patients. This study provided a reference for further investigation and
evaluation of the role of pharmacists in preventing heart failure in the high-risk community elderly patients.
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Background
Heart Failure (HF) is a serious condition worldwide,
with around 5.7 million people in United States of
America being the victims. Also, the disease was
found to be a contributing cause in more than
280,000 deaths (1 in 9) in 2008 [1].The American
Heart Association has also suggested about half of
people who have heart failure die within 5 years of
diagnosis [1] and hence the problem should not be
neglected. It has been reviewed that the population
suffering from heart failure is expanding in Asia, par-
ticularly in areas like Hong Kong, due to improved
living standards [2]. In Hong Kong, cardiovascular
diseases rank the second leading cause of death in
age group 65 or above according to the Department
of Health [3]. These findings imply primary interven-
tions must be carried out promptly to deal with the
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problem, in accordance with the Heart Failure Society
of America (HFSA) suggestion that early identification
and treatment of risk factors are recognized of utmost
importance in limiting the public health impact of
heart failure [4].
It has been investigated that hypertension [4, 5, 7],
diabetes mellitus [4, 5, 6, 7] and hyperlipidemia [4, 6]
are the major causes of HF. To effectively prevent
HF, blood pressure (BP), blood glucose and choles-
terol level shall be closely monitored and controlled.
Moreover, medication compliance plays an incumbent
role to achieve desirable therapeutic outcomes [7]. It
reduces incidents of hospitalization as well as the
healthcare cost [8] in community elderly patients,
their compliance to medical regimen shall be empha-
sized to prevent HF. A foreign study has shown that
home-based intervention performed by pharmacists
could significantly reduce mortality and recurrent
hospitalization in HF patients [9]. Meanwhile, local
studies suggest that a pharmacy outreach service
(POS) for community elderly patients can effectively
improve BP control [10] and drug related problems
(DRPs) [11]. Besides, it has been illustrated that phar-
macists have an established role in managing DRPs in
elderly patients, including drug-drug interactions and
therapeutic duplications [12]. This study aimed to
investigate the role of pharmacist intervention in the
early identification of HF symptoms in high-risk
elderly patients in the community. We therefore
conducted a series of POS visits to perform pharma-
cist interventions on managing the risk factors of HF
in the high-risk community elderly patients, hyperten-
sion, diabetes, hyperlipidemia as well as reviewing
their medication compliance, for the prevention of HF.
Methods
This was a prospective uncontrolled study of which
subjects were recruited from seven elderly centers in
Hong Kong during the Pharmacy Outreach Service
in July and August 2012. Patients with recent symp-
toms of HF were included in this study. These
symptoms were evaluated by a questionnaire de-
signed to correspond to the New York Heart Associ-
ation (NYHA) functional classification of HF. High-
risk subjects would also be selected, defined as two
out of three of the following criteria were met:
1. High blood pressure as defined in Joint National
Committee (JNC) 7 [13]: ≥ 130/80mmHg for
diabetic patients and ≥ 140/90mmHg for non-
diabetic patients
2. High blood glucose as defined in Standard of
Medical Care in Diabetes 2012 [14]: RCBG ≥
11.1mmol/L
3. Dyslipidemia as defined in ATP III [15]: LDL level ≥
2.59mmol/L or TG ≥ 2.3mmol/L
Patients who were younger than 65 years old or diag-
nosed with the following medical conditions, namely
malignancies, dementia, psychiatric disorders, Alzhei-
mer’s diseases, Parkinson’s diseases or epilepsy, were ex-
cluded in the study. Patients without the need of
pharmacological management of their hypertension, dia-
betes, or dyslipidemia were also excluded. Other exclu-
sion criteria include previous participations in the
Chinese University of Hong Kong (CUHK) Outreach
Service, current involvement in other clinical trials and
the presence of communication barriers. The current
project was approved by the Joint Chinese University of
Hong Kong-New Territories East Cluster (CUHK-
NTEC) Clinical Research Ethics Committee (Reference
number: 2014.012). All recruited subjects had been con-
sented prior to joining the current project.
Subjects were revisited twice every 3 to 4 months
from October 2012 to November 2012 and from Feb-
ruary 2013 to April 2013. At each visit, subjects’ BP,
RCBG level and cholesterol level were measured, and
their demographic data and medication profiles were
reviewed and recorded. The Omron HEM-7011 elec-
tronic blood pressure monitor (Omron Healthcare,
Kyoto, Japan) was used for measuring the blood pres-
sure. This electronic device had achieved an “A/A”
performance classification under the British Hyperten-
sion Society criteria and passed the Association for
the Advancement of medical instrumentation require-
ments [16]. The random blood glucose level was mea-
sured with Accu-Chek® Performa (Roche Diagnostics,
Fig. 1 Workflow of each visit
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Switzerland). The lipid panel of each subject was
measured with a CardioChek® Analyzer (Polumer
Technology Systems Inc., USA). By using the battery-
operated analyzer, four categories of measurements
were collected, namely total cholesterol (TC), high-
density lipoprotein (HDL), low-density lipoprotein
(LDL) and triglyceride (TG), from fingerstick capillary
samples [17]. The test system is intended for in vitro
diagnostic use to test whole blood [18].
The workflow of each visit is summarized in Fig. 1.
Pharmacists counseled on the use of medications, dis-
ease knowledge and provided non-pharmacological mea-
sures for disease management. Interventions were made
with regard to any DRPs identified. Additionally, evalu-
ation on signs and symptoms of HF by a questionnaire
(Additional file 1) corresponding to the NYHA func-
tional classification and assessment on medication com-
pliance by the Morisky 8-item Medication Adherence
Scale were performed at the first and last visit.
The baseline data were compared to those obtained in
the last follow-up visit in order to analyze the impacts of
POS on community elders’ management of risk factors
associated with HF. McNemar’s test was used for the as-
sessment of HF symptoms while paired t-test was uti-
lized to detect changes in BP, RCBG, cholesterol levels
and Morisky Medication Adherence Scale. According to
previous POS studies [19–21], mean standard deviation
of the change of systolic and diastolic blood pressures
are 10.67 and 8.55mmHg respectively.
The number of subject needed was calculated using
the equation below [22]:




At least 40 subjects would be required to identify a
10mmHg change of the systolic blood pressure and at
least 26 subjects would be needed to identify a change in
10mmHg of diastolic blood pressure with a power of
80%, a significance level of 0.05 and with an assumption
of 40% drop-out rate. Therefore, at least 66 subjects
would be required.
All statistical analysis were performed using SPSS 16.0
and a p value of <0.05 was defined as statistically
significant.
Results
We screened 297 patients and a total of 103 patients
were recruited. The demographic characteristics and
medical history of participants is summarized in
Table 1. The mean age of participants was 78.19 ±
6.87 years old, and they were taking an average of
5.08 ± 3.02 chronic medications. For the HF symp-
toms assessment, a significant increase in number of
31.88% subjects (p < 0.001) were found to be free of
symptoms of HF, spanning the period between base-
line and the last visit. A significant reduction of
mean number of HF symptoms experienced by each
subject was observed (p < 0.001). In addition, there
were fifteen less elderly patients (-21.74%, p = 0.001,
Table 2) experienced four or more symptoms at the
end of the study. It was observed that more than
half (52.17%) of the subjects reported to have limita-
tion of physical activity at baseline and the number
was significantly reduced at the end of the study
(-26.09%, p = 0.001) based on the questionnaire. The
other HF symptoms that were found to be sensitive to
pharmacist intervention included, shortness of breath
(-18.84%, p = 0.004), fatigue easily (-17.39%, p = 0.029),
edema (-17.39, p = 0.008) and physical activity limitation
when climbing stairs in particular (-18.84%, p = 0.015)
(Table 2).
For the impact of POS on the risk factors management
of heart failure, namely hypertension, diabetic mellitus
and hyperlipidemia, no significant improvement was ob-
served in BP and glycemic control in overall participants.
However, significant reduction in SBP level (-14.45 ±
17.97mmHg, p = 0.024) was achieved in subjects with
Stage II hypertension. The reduction of RCBG level
(-3.70 ± 2.44mmol/L, p = 0.004) was also significant in
not well-controlled subjects (Table 3). For lipid control,
significant improvement was achieved in overall partici-
pants, with significant reduction in LDL-cholesterol level
(-0.86 ± 0.56mmol/L, p = 0.038), and in triglyceride level
(-1.15 ± 1.09mmol/L, p < 0.001).
Non-compliance to medications is also a contributing
factor of HF, 66.99% of the elderly patients were identi-
fied to be medication non-compliant. The Morisky score
results showed a significant reduction in mean score by
0.54 ± 1.50 (p = 0.005) (Table 4). At the baseline, 27.54%
of the subjects were considered as low compliance sub-
jects and there was a slight but insignificant reduction in
the number at the end of the study (-4.35%, p = 0.607).
In addition, results showed a significant increase by
23.19% (p = 0.001) in the number of subjects with high
compliance level. Forgetfulness (30.4%) was found to be
the most common reason for non-compliance, followed
by improper administration time (20.3%) and fear of ad-
verse drug reaction (18.8%).
Discussion
It has been suggested by HFSA that patients at risk of
cardiovascular disease are also at high risk for develop-
ing HF, and early identification and treatment of risk fac-
tors are recognized of utmost importance in limiting the
public health impact of HF [4]. Hypertension, hyperlip-
idemia, diabetes mellitus and unhealthy lifestyle are rec-
ognized as potential risk factors for the development of
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myocardial remodeling, cardiac dysfunction and hence
HF. In the study, subjects were being assessed with the
presence of HF symptoms using the HF Symptoms As-
sessment Questionnaire via self-reporting method. There
were a total of 16 questions in the questionnaire that cor-
respond to ten symptoms of HF. Significant reduction in
number of HF symptoms experienced by each subject as
well as number of subjects experienced four or more
symptoms were observed, which demonstrated the
changes before and after the pharmacists’ interventions.
Although the changes may not be solely due to the phar-
macists’ intervention due to the lack of control group in
the current study. It demonstrated the potential essential
role of pharmacist intervention upon better disease con-
trol and minimizing risk of HF in community elderly pa-
tients. These results correlate to a previous study
suggesting that pharmacists have an incumbent role in the
community in HF management [16].
In addition, the role of pharmacist in managing risk
factors of HF was also investigated in the study.
Table 1 Baseline characteristics of the study participants
Subject characteristics N = 103 (%)
Age, mean ± SD, years 78.19 ± 6.87
Male sex 31 (29.66)
Literate 83 (80.58)







Amount per week,mean ± SD, minutes 243.43 ± 202,19
- Less than 150 min per day 36(34.95)
− 150 min or above 62 (60.19)
- Unknown 5 (4.85)
Disease Status at baseline visit
Uncontrolled blood pressure level 57 (55.34)
- Stage II Hypertensiona 19/57 (33.33)
Uncontrolled RCBG levelb 20(19.42)
Uncontrolled cholesterol levels 56(54.37)
- Uncontrolled LDL-C levelc 21/56(37.50)
- Uncontrolled TG leveld 46/56 (82.14)
- Both uncontrolled LDL-C and TG levels 11/56(19.64)
Present with symptoms of heart failure corresponding to NYIIA Functional Classification system 87 (84.47)
Medical history
Hypertension 97 (94.17)
Diabetes mellitus 44 (42.72)
Hyperlipidemia 76(73.79)




Number of chronic medications, mean ± SD 5.08 ± 3.02
a: Non-stage II - Systolic blood pressure < 160mmHg Or Diastolic blood pressure < 100mmHg
Stage II - Systolic blood pressure≧160mmHg Or Diastolic blood pressure≧100mmHg (JNC 7 Guideline [13])
b: Uncontrolled RCBG level: ≥ 11.1 mmol/L (ADA [14])
c: Uncontrolled LDL-C level: ≥ 2.59 mmol/L (ATP III [15])
d: Uncontrolled TG level : ≥ 2.3mmol/L (ATP III [15])
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According to the US NHANES I Epidemiologic Follow-
up Study, not well-controlled hypertension was found to
be positively and significantly associated to increased
risk of HF [17]. This study has shown no significant im-
provement in the BP management in overall partici-
pants, however in subgroup analysis, statistically
significant reduction in SBP level was detected in partici-
pants with stage-II hypertension at baseline. This result
is consistent with a previous study which has shown that
hypertensive patients with baseline SBP ≥160mmHg
would have a more significant decrease in BP than the
others who have lower BP baseline after pharmacist
intervention [25]. Therefore, hypertensive patients, who
are of higher risk to developing HF, are more sensitive
to pharmacist intervention in the prevention of HF.
It was clearly established in prior studies that diabetes
is a risk factor for HF [26-29]. In the study, no signifi-
cant improvement in glycemic control was observed in
overall participants. The reason for the insignificant re-
sult might be due to the fact that RCBG level was highly
subjected to the influence of various confounding fac-
tors, such as time elapsed after food intake. As a result,
RCBG level might not able to truly reflect the impact of
pharmacist intervention on glycemic control in overall
participants. Improvement in study design, such as
measuring HbA1c level instead of RCBG level, is sug-
gested in future investigation.
HFSA has suggested that hyperlipidemia is a risk fac-
tor for the development of HF [4]. Meanwhile, since
hyperlipidemia is one of the risk factors for the develop-
ment of CHD [30], well control of cholesterol levels,
particularly LDL-cholesterol level, can reduce risk of
CHD and subsequently myocardial remodeling and heart
failure. This study has showed that pharmacist interven-
tion significantly reduce LDL-cholesterol level as well as
triglyceride level in overall participants. In the sub-group
analysis, subjects with not well-controlled cholesterol
levels were found to be more sensitive to pharmacist
intervention in managing hyperlipidemia. Precedent
studies have found that regular pharmacist follow-up
and intervention for patients on disease education, chol-
esterol measurement, medication compliance and refer-
ral to physician can improve cholesterol management in
high-risk patients [31, 32]. Systemic review also showed
that community pharmacy-based service contributed to
the reduction in risk factors for CHD regarding lipid
management [17]. Therefore, pharmacist intervention in
POS may contribute in prevention HF in community
Table 2 Summary of various heart failure symptoms experienced by subjects based on the heart Failure Symptoms Assessing
Questionnaire at baseline and latest follow-up visit, N = 69
Question no. Symptoms of heart failure Baseline n(%) Latest visit, n(%) Difference, n(%) P value
1 Chest pain 22 (31.88) 13(18.84) −9 (13.04) 0.064
2 Shortness of breath 22 (31.88) 9(13.04) −13 (18.84) 0.004
3 Dyspnea 10 (14.49) 5 (7.25) −5(7.25) 0.125
4 Dizziness or fainting when position changed 18 (26.09) 10 (14.49) -8 (11.59) 0.057
5 Dyspnea when. lying down 3 (4.35) 5 (7.25) +2 (2.90) 0.727
6 Fatigue easily 35 (50.72) 23 (33.33) −12 (17.39) 0.029
7 Edema 22 (33.33) 11 (15.94) −12(17.39) 0.008
8 Sleeping pattern disturbed due to difficulty breathing 10 (14.49) 7(10.14) −3 (4.35) 0.549
9 Idiopathic cough 10 (14.49) 4 (5.80) −6(8.70) 0.109
10 Limitation of physical activity 36 (52.17) 18 (26.09) −18 (26.09) 0.001
10a - Discomfort when climbing stairs 31 (49.28) 18 (26.09) −13 (18.84) 0.015
10b - Discomfort when walking 9(13.04) 5 (7.25) -4 (5.80) 0.344
10c - Discomfort at rest 2 (2.90) 5 (7.25) +3 (4.35) 0.375
Total no. of subject symptoms of heart failure 63 (91.30) 41 (59.42) −22 (31.88) <0.001
No. of symptoms experienced by individual, mean ± SD 2.96 ± 1.93 1.52 ± 1.91 −1.43 ± 1.90 <0.001
Symptoms experienced by most subjects Limitation of physical activity Fatigue easily
2nd most symptoms experienced by subjects Fatigue easily Limitation of physical activity
No. of subjects experienced
1 symptom 10 (14.49) 15(21.74) +5 (7.25) 0.225
2 symptoms 14 (3.0.29) 9(13.04) −5(7.25) 0.251
3 symptoms 15 (21.74) 8 (11.59) −7 (10.14) 0.108
≥4 symptoms 24 (34.73) 9(13.04) −15(21.74) 0.001
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elderly patients but further investigation shall be con-
ducted to provide solid evidence on this issue.
Several studies have suggested that non-compliance
can be a precipitating factor of HF exacerbation [18, 33]
as well as impairing the chronic disease management
[34]. Pharmacist therefore are in ideal position to evalu-
ate patients’ compliance and aid them to improve their
medication compliance. Therefore, it is essential for
pharmacist to ensure patients with chronic diseases are
compliance with medications to prevent HF or its
Table 4 Identified causes of non-compliance and the compliance score at Baseline and the latest Follow-up visit, N = 69




Improper administration time 14/69 (20.29)
Improper administration method 3/69 (4.35)
Overuse of “PRN” drugs 3/69 (4.35)
Underuse of “PRN” drugs 1/69(1.45)
Fear of Adverse drug reaction 13/69(18.84)
Think no need 7/69(10.14)
Pill splitting method 2/69 (2.9)
Compliance scoreJ
Baseline Latest Difference p value
mean ± SD 1.93(±1.78) 1.39(±1.80) −0.54(±1.50) 0.005
No. of Low adherence subjectk,n(%) 19 (27.54) 16(23.19) −3 (4.35) 0.607
No. of Medium adherence subjectk’, n (%) 33 (47.83) 20 (28.99) −13(18.84) 0.011
No. of High adherence subjectk, n (%) 17(24.64) 33 (47.83) +16(23.19) 0.001
J: Compliance based on Morisky questionnaire
k: Low adherence - Morisky Scores >2; Medium adherence - Morisky Scores = 1 or 2; High adherence - Morisky Scores = 0
Table 3 Comparison of blood pressure, random capillary blood glucose and cholesterol level between baseline and the latest
follow-up visit
Systolic blood pressure (SBP) level (mean ± SD, mmHg)
N Baseline Latest Difference P value
All 61 142.11 ± 19.73 145.00 ± 19.37 +2.89 ± 22.02 0.310
Uncontrolled subjecta 11 169.27 ± 11.59 154.82 ± 16.32 −14.45 ± 17.97 0.024
Diastolic blood pressure (DBP) level (mean ± SD, mmHg)
All 61 70.20 ± 10.70 71.87 ± 9.54 +1.67 ± 10.35 0.256
Uncontrolled subjecta 11 71.00 ± 9.96 72.45 ± 11.24 +1.24 ± 13.49 0.728
Random capillary blood glucose (RCBG) level (mean ± SD, mmol/L)
All 61 7.81 ± 2.79 7.78 ± 2.89 −0.03 ± 2.96 0.938
Uncontrolled subjectb 8 13.45 ± 2.57 9.75 ± 3.63 −3.70 ± 2.44 0.004
LDL-cholesterol level (mean - SD, mmol/L)
All 57 2.23 ± 0.91 2.05 ± 0.57 −0.19 ± 0.66 0.038
Uncontrolled subjectc 17 3.42 ± 0.54 2.56 ± 0.46 −0.86 ± 0.56 <0.001
Triglyceride level (mean ± SD, mmol/L)
All 60 2.40 ± 1.11 1.71 ± 0.90 −0.68 ± 1.01 <0.001
Uncontrolled subjectd 30 3.28 ± 0.86 2.13 ± 1.00 −1.15 ± 1.09 <0.001
a: uncontrolled subjects with SBP/DBP >140/90 mmHg or >130/80 mmHg (DM patients) (JNC 7 [13])
b: uncontrolled subjects” with baseline RCBG > 11.1 mmol/L (ADA [14])
c: uncontrolled subjects with LDL-level > 2.59 mmol/L(ATP III [15])
d: uncontrolled subjects with TG-level >2.3 mmol/L(ATP III [15])
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progression. In this study, the Morisky score results
showed a significant improvement in medication compli-
ance among subjects with pharmacist intervention, which
provide medical education on individual’s regimen. Over
66% of subjects were identified to have non-compliance
issue, which is one of the well-known common DRPs in
elderly patients [35]. Out of the various reasons behind
the non-compliance issue, forgetfulness contributed the
most (30.4%). Forgetfulness is classified as an uninten-
tional cause of non-compliance. Previous study [36] illus-
trates the importance of pharmacist’s intervention in
providing memory aids, educating measures to take if a
dose is missed and suggesting the use of medication com-
pliance calendars. Therefore, additional compliance aids
and education shall be provided in the future POS.
Limitations
The current study has several limitations. There was selec-
tion bias during sampling since this was not a randomized
trial, which was also reflected in the unequal distribution
in gender in the sample. There were more female subjects
involved in the POS probably due to their better health-
seeking behavior but this was consistent with the previous
POS [10]. A randomized controlled trial with cross-over
design might be considered not only to reduce the selec-
tion bias but also to provide a more concrete evidence for
the benefits of pharmacist interventions. Furthermore,
only seven elderly centers participated in this study and
this may not be truly reflecting the situation in Hong
Kong. We did not assess the echocardiography results to
confirm the impact of POS. The compliance assessment
was based on self-reporting from the patients. The current
HF questionnaire developed for this study was not vali-
dated and therefore may not be applicable for patients
outside Hong Kong. Not all risk factors were examined in
this study. The sample size of the current study was small
and Hong Kong-based. As a result, the study may be
underpowered and not be able to generalize to other
countries with a larger population.
Conclusion
Pharmacy outreach service has significantly improved
HF symptoms management and medication compliance
in the high-risk community elderly patients. It has also
improved cholesterol management in overall subjects.
Further investigation with improved study design shall
be conducted in order to evaluate and provide sound
evidence on pharmacist role in preventing HF in com-
munity elderly patients.
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